Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4248565
Max Phase: Preclinical
Molecular Formula: C55H106N20O10
Molecular Weight: 1207.58
Molecule Type: Small molecule
Associated Items:
ID: ALA4248565
Max Phase: Preclinical
Molecular Formula: C55H106N20O10
Molecular Weight: 1207.58
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C
Standard InChI: InChI=1S/C55H106N20O10/c1-29(2)25-39(67-34(11)76)48(81)72-41(27-31(5)6)50(83)74-42(28-32(7)8)51(84)73-40(26-30(3)4)49(82)70-38(20-16-24-66-55(62)63)47(80)75-43(33(9)10)52(85)71-36(17-12-13-21-56)46(79)69-37(19-15-23-65-54(60)61)45(78)68-35(44(57)77)18-14-22-64-53(58)59/h29-33,35-43H,12-28,56H2,1-11H3,(H2,57,77)(H,67,76)(H,68,78)(H,69,79)(H,70,82)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,80)(H4,58,59,64)(H4,60,61,65)(H4,62,63,66)/t35-,36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
Standard InChI Key: NGTHYENJBQAZNI-GMIRWQTLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1207.58 | Molecular Weight (Monoisotopic): 1206.8401 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.. (2018) Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines., 61 (18): [PMID:30180568] [10.1021/acs.jmedchem.8b01144] |
Source(1):